Get the SPI Wire

Entera Bio Ltd.

NASDAQ:ENTX
Annual Meeting

of Shareholders

MEETING DATE

11/24/2026
DEF 14A FILED
10/14/2026
PUBLISHED
10/14/2026 8:05 pm
TIME TO PUBLISH
10/16/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:ENTX · CUSIP M40527109 · CLASS ordinary shares, par value NIS 0.0000769 per share · CIK 0001638097

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

8
FOR
0
AGAINST
0
WITHHOLD
8
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
To approve an amendment to the Company’s 2018 Equity Incentive Plan to increase the number of Ordinary Shares issuable thereunder by 13,937,915 Ordinary Shares
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the increase supports Private Placement-related grants and anticipated hiring and retention needs.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
To approve a one-time equity grant to Ms. Miranda Toledano, our Chief Executive Officer and a Director
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the award restores the CEO’s fully diluted ownership percentage after the Private Placement.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
To approve a one-time equity grant to Ms. Dana Yaacov-Garbeli, our Chief Financial Officer
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the award restores the CFO’s fully diluted ownership percentage after the Private Placement.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
To approve a one-time equity grant to Mr. Hillel Galitzer, our Chief Operating Officer
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the award restores the COO’s fully diluted ownership percentage after the Private Placement.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
5
To approve a one-time equity grant to Mr. Gregory Burshtein, our Chief of Research and Development
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the award restores R&D leadership’s fully diluted ownership percentage after the Private Placement.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
6
To approve the amended and restated compensation policy for the directors and officers of the Company
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

External compensation surveys stated executive compensation levels were below market benchmarks.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
7
To approve the amended terms of compensation of the Company’s non-executive directors
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

External survey found non-executive director equity compensation was below market and not competitive.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
8
To approve the extension of the post-termination exercise period for share options granted or to be granted to the Company’s officers and directors
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the amendment extends the exercise period from three months to five years.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

8618e1d98cea3b1e2a65aa556711f238b9df37dc17fa4256c86fb1aa03b02560

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates